CHMP Recommends Approval of Lilly and Incyte’s OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
- Friday, May 20, 2022, 7:14
- Business
- Add a comment
INDIANAPOLIS, May 20, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the…
About the Author
adminasapcorp has written 41633 stories on this site.